{"id":941017,"date":"2026-03-02T09:32:00","date_gmt":"2026-03-02T14:32:00","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-upcoming-investor-conferences-2\/"},"modified":"2026-03-02T09:32:00","modified_gmt":"2026-03-02T14:32:00","slug":"altimmune-to-participate-in-upcoming-investor-conferences-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-upcoming-investor-conferences-2\/","title":{"rendered":"Altimmune to Participate in Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p>GAITHERSBURG, Md., March  02, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=y842bIPsZpxkg8oYUc6Rz7Rps2P29hghAK6HBY3_J8aGxf0dm0GHJWgQ5s6weKrNqpqoIB44B_vz0TII3of-ng==\" rel=\"nofollow\" target=\"_blank\">Altimmune, Inc.<\/a> (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate and be available for one-on-one meetings at the following investor conferences:<\/p>\n<ul type=\"disc\">\n<li>\n          <strong>Leerink Global Healthcare Conference <\/strong><br \/>\n          <br \/>Monday, March 9, 2026 \u2013 <em>One-on-one meetings<\/em><br \/>Wednesday, March 11, 2026 \u2013 <em>Fireside chat at 9:20 a.m. ET<\/em><\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>\n          <strong>Citizens Life Sciences Conference <\/strong><br \/>\n          <br \/>Tuesday, March 10, 2026 \u2013 <em>One-on-one meetings<\/em><br \/><em>Fireside chat at 2:15 p.m. ET<\/em><\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>\n          <strong>Jefferies Biotech on the Beach Summit<\/strong><br \/>\n          <br \/>Wednesday, March 11, 2026 \u2013<em> One-on-one meetings only<\/em><\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>\n          <strong>Barclays 28<\/strong><br \/>\n          <sup><br \/>\n            <strong>th<\/strong><br \/>\n          <\/sup><br \/>\n          <strong> Annual Global Healthcare Conference<\/strong><br \/>\n          <br \/>Thursday, March 12, 2026 \u2013<em> One-on-one meetings <\/em><br \/><em>Fireside chat at 10:30 a.m. ET<\/em><\/li>\n<\/ul>\n<p>Webcasts of the fireside chats at the Leerink, Citizens and Barclays conferences will be available via the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fse1ecO750tawqEcYM38UJHEalsqZKG94VH7aQkB5FwS9J8efSZP4_3_r7V24MLoBEFXERWxScV8gU0qU-TFR21Eg16NGBw6VeMmeoBu4mpbeb_zQkxiTnS8kxYemf6h\" rel=\"nofollow\" target=\"_blank\">Events<\/a> section of the Altimmune website.<\/p>\n<p>Registered investors may request meetings on the dates noted above via their sales contacts at the respective banks.<\/p>\n<p>\n        <strong>About Altimmune<\/strong><br \/>\n        <br \/>Altimmune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company\u2019s lead candidate, pemvidutide, is a unique dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uAD00z-2RQZq6pAeFzAJxRc2_rPqKy4T4D2-PJ-5qAlvn1iuADAsvioaQBCGujjW7P-cD5J2iu5KWeUDsYYYi0ei9f5RQHrZ33_qSiOqY4o=\" rel=\"nofollow\" target=\"_blank\">www.altimmune.com<\/a>.<\/p>\n<p>\n        <strong>Follow @Altimmune, Inc. on <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Z4TGdXkPf7SNaePXM7b6myKQUIbHNftKvCzaVBsUp1uQrj2maSNse1warQREbJ5dgUgYuY-lGlHDunjMmoDR9tsjyfUr3Ajqh-PdU_gr8Os=\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong>LinkedIn<\/strong><br \/>\n        <\/a><br \/>\n        <br \/>\n        <strong>Follow @AltimmuneInc on <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=B48rTZTwmwlNov49j2AeUyh7XQxCC3EwVH1jeI72yl9uwmggQtxdkv0dghzR_V77ZjQT5ifp1SimBXe3Nqfr-A==\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong>X<\/strong><br \/>\n        <\/a>\n      <\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Lee Roth<br \/>Burns McClellan<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ueU0dUkrkQ4V-7ZwJ-dBltizY3DtDeDGi1C09mB5hShmeYvMls9oUcF10bK94ixg0_zghDCTrjmzefg0DTicPWYIfPmLBvXzApTmDDTjEY0=\" rel=\"nofollow\" target=\"_blank\">lroth@burnsmc.com<\/a><\/p>\n<p>\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Real Chemistry<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5xbDBnMe1Tcv8XZnDfMBiMHiU5ZVOjTtUpnBsE6s077c_Cmt3F0jbYEJ_kIdSCiG92aLiHN82J-wSEjdXDSvGL0LFUIoeX0X0L1MEUVOLFjXyPrQfZ6Apjtb1Le7S9pE\" rel=\"nofollow\" target=\"_blank\">altimmune@realchemistry.com<\/a><\/p>\n<p>This press release was published by a CLEAR\u00ae Verified individual.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2MzQwNiM3NDYwNzk3IzIwMTA2NzY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MjJhNTU2NzgtYjJlOC00MDg1LWJjYmYtNTY1MzU3ZmY3MzBmLTEwMjIyNDktMjAyNi0wMy0wMi1lbg==\/tiny\/Altimmune-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>GAITHERSBURG, Md., March 02, 2026 (GLOBE NEWSWIRE) &#8212; Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate and be available for one-on-one meetings at the following investor conferences: Leerink Global Healthcare Conference Monday, March 9, 2026 \u2013 One-on-one meetingsWednesday, March 11, 2026 \u2013 Fireside chat at 9:20 a.m. ET Citizens Life Sciences Conference Tuesday, March 10, 2026 \u2013 One-on-one meetingsFireside chat at 2:15 p.m. ET Jefferies Biotech on the Beach Summit Wednesday, March 11, 2026 \u2013 One-on-one meetings only Barclays 28 th Annual Global Healthcare Conference Thursday, March 12, 2026 \u2013 One-on-one meetings Fireside chat at 10:30 a.m. ET Webcasts of the fireside chats at the Leerink, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-upcoming-investor-conferences-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Altimmune to Participate in Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-941017","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Altimmune to Participate in Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-upcoming-investor-conferences-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Altimmune to Participate in Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"GAITHERSBURG, Md., March 02, 2026 (GLOBE NEWSWIRE) &#8212; Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate and be available for one-on-one meetings at the following investor conferences: Leerink Global Healthcare Conference Monday, March 9, 2026 \u2013 One-on-one meetingsWednesday, March 11, 2026 \u2013 Fireside chat at 9:20 a.m. ET Citizens Life Sciences Conference Tuesday, March 10, 2026 \u2013 One-on-one meetingsFireside chat at 2:15 p.m. ET Jefferies Biotech on the Beach Summit Wednesday, March 11, 2026 \u2013 One-on-one meetings only Barclays 28 th Annual Global Healthcare Conference Thursday, March 12, 2026 \u2013 One-on-one meetings Fireside chat at 10:30 a.m. ET Webcasts of the fireside chats at the Leerink, &hellip; Continue reading &quot;Altimmune to Participate in Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-upcoming-investor-conferences-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-02T14:32:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2MzQwNiM3NDYwNzk3IzIwMTA2NzY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-participate-in-upcoming-investor-conferences-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-participate-in-upcoming-investor-conferences-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Altimmune to Participate in Upcoming Investor Conferences\",\"datePublished\":\"2026-03-02T14:32:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-participate-in-upcoming-investor-conferences-2\\\/\"},\"wordCount\":243,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-participate-in-upcoming-investor-conferences-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2MzQwNiM3NDYwNzk3IzIwMTA2NzY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-participate-in-upcoming-investor-conferences-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-participate-in-upcoming-investor-conferences-2\\\/\",\"name\":\"Altimmune to Participate in Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-participate-in-upcoming-investor-conferences-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-participate-in-upcoming-investor-conferences-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2MzQwNiM3NDYwNzk3IzIwMTA2NzY=\",\"datePublished\":\"2026-03-02T14:32:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-participate-in-upcoming-investor-conferences-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-participate-in-upcoming-investor-conferences-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-participate-in-upcoming-investor-conferences-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2MzQwNiM3NDYwNzk3IzIwMTA2NzY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2MzQwNiM3NDYwNzk3IzIwMTA2NzY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-participate-in-upcoming-investor-conferences-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Altimmune to Participate in Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Altimmune to Participate in Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-upcoming-investor-conferences-2\/","og_locale":"en_US","og_type":"article","og_title":"Altimmune to Participate in Upcoming Investor Conferences - Market Newsdesk","og_description":"GAITHERSBURG, Md., March 02, 2026 (GLOBE NEWSWIRE) &#8212; Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate and be available for one-on-one meetings at the following investor conferences: Leerink Global Healthcare Conference Monday, March 9, 2026 \u2013 One-on-one meetingsWednesday, March 11, 2026 \u2013 Fireside chat at 9:20 a.m. ET Citizens Life Sciences Conference Tuesday, March 10, 2026 \u2013 One-on-one meetingsFireside chat at 2:15 p.m. ET Jefferies Biotech on the Beach Summit Wednesday, March 11, 2026 \u2013 One-on-one meetings only Barclays 28 th Annual Global Healthcare Conference Thursday, March 12, 2026 \u2013 One-on-one meetings Fireside chat at 10:30 a.m. ET Webcasts of the fireside chats at the Leerink, &hellip; Continue reading \"Altimmune to Participate in Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-upcoming-investor-conferences-2\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-02T14:32:00+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2MzQwNiM3NDYwNzk3IzIwMTA2NzY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-upcoming-investor-conferences-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-upcoming-investor-conferences-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Altimmune to Participate in Upcoming Investor Conferences","datePublished":"2026-03-02T14:32:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-upcoming-investor-conferences-2\/"},"wordCount":243,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-upcoming-investor-conferences-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2MzQwNiM3NDYwNzk3IzIwMTA2NzY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-upcoming-investor-conferences-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-upcoming-investor-conferences-2\/","name":"Altimmune to Participate in Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-upcoming-investor-conferences-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-upcoming-investor-conferences-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2MzQwNiM3NDYwNzk3IzIwMTA2NzY=","datePublished":"2026-03-02T14:32:00+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-upcoming-investor-conferences-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-upcoming-investor-conferences-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-upcoming-investor-conferences-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2MzQwNiM3NDYwNzk3IzIwMTA2NzY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2MzQwNiM3NDYwNzk3IzIwMTA2NzY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-upcoming-investor-conferences-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Altimmune to Participate in Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/941017","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=941017"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/941017\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=941017"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=941017"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=941017"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}